Literature DB >> 26301564

Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?

Kristen P Bunch1, Christina M Annunziata1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26301564     DOI： 10.1002/cncr.29394

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Authors:  Lois M Ramondetta; Wei Hu; Premal H Thaker; Diana L Urbauer; Gary B Chisholm; Shannon N Westin; Yunjie Sun; Pedro T Ramirez; Nicole Fleming; Sunil K Sahai; Alpa M Nick; Jesusa M G Arevalo; Thomas Dizon; Robert L Coleman; Steve W Cole; Anil K Sood
Journal:  Gynecol Oncol       Date:  2019-07-25       Impact factor: 5.482

Review 2.  The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review.

Authors:  J Hefner; H Csef
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

3.  Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.

Authors:  Kristan H Cleveland; Sherry Liang; Andy Chang; Kevin M Huang; Si Chen; Lei Guo; Ying Huang; Bradley T Andresen
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.240

4.  Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.

Authors:  Min Hyun Baek; Dae Yeon Kim; Seon Ok Kim; Ye Jee Kim; Young Han Park
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.